Table 1.

Main studies reporting molecular alterations associated with biliary tract cancers

First author	Platform/genes analyzed	N of patients	Genomic alterations (%)
Nakamura et al. (13)	WES	260	ICC: KRAS 25%, FGFR2 8%, IDH1 6%; EHC: TP53 26%, KRAS 12%, SMAD4 10%; GBC: TP53 43%, ARID2 18%, EGFR 18%
Javle et al. (14)	HC NGS 182	ICC 412; EHC 57; GBC 85	ICC: TP53 27%, KRAS 22%, IDH1 16%; EHC: KRAS 42%, TP53 40%, SMAD4 21 %; GBC: TP53 59%, CDKN2A/B 19%, ERBB2 16%
Lowery et al. (15)	HC NGS 341/410	ICC 158; EHC 37	ICC: IDH1 30%, BAP1 20%, FGFR2 14%; EHC: KRAS 38%, TP53 49%, SMAD4 30%
Narayan et al. (16)	HC NGS 341/410	GBC 81	TP53 58%, SMAD4 31%, ARID1A 25%
Churi et al. (17)	AB NGS 46	ICC 55; EHC 20	ICC: TP53 29%, KRAS 24%, IDH 24%; EHC: KRAS 40%, TP53 45%, SMAD4 25%
Li et al. (18)	WES	GBC 57	TP53 47%, ERBB3 12%, KRAS 8%
Ross et al. (19)	HC NGS 182	ICC 28	ARID1A 36%, IDH1/2 36%, TP53 36%
Zou et al. (20)	WES	ICC 102	TP53 38%, KRAS 17%, ARID1A 7%

WES, whole-exome sequencing; HC NGS, hybrid capture next generation sequencing; AB NGS, amplicon-based next generation sequencing; ICC, intrahepatic cholangiocarcinoma; EHC, extrahepatic cholangiocarcinoma; GBC, gallbladder cancer.